The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) has emerged as a standout performer in the financial markets today, September 26, 2025, with its stock experiencing a dramatic surge. The significant uptick, which saw shares climb by over 52% in premarket trading and reach highs of 79% and 60.71% during Friday's session,
Join us as we analyze Quest Diagnostics and uncover whether this lab giant is a smart investment choice for the future. With insights from industry experts, you won't want to miss this evaluation!
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting with Quest (NYSE:DGX).
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.2% year on year to $2.76 billion. The company’s full-year revenue guidance of $10.86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.64 per share was 2.5% above analysts’ consensus estimates.
Shares of healthcare diagnostics company Quest Diagnostics (NYSE:DGX)
jumped 6.4% in the morning session after the company reported strong second-quarter financial results that beat Wall Street expectations and raised its full-year guidance.
